Skip to main content
Premium Trial:

Request an Annual Quote

DNA Genotek, WeGene Ink DNA Collection Device Supply Deal

NEW YORK (GenomeWeb) – OraSure Technologies subsidiary DNA Genotek announced today that it has signed a multi-year agreement to supply DNA collection kits to Chinese personal genomics firm WeGene.

According to DNA Genotek, WeGene will use the Oragene-DNA — an all-in-one system for the self collection and stabilization of DNA in saliva — for its genetic testing and personalized healthcare services. Additional terms were not disclosed.

"We are committed to creating a superior personalized medicine and ancestry offering tailored to the East Asian population," WeGene CEO Qiang Zheng said in a statement. "A key enabler to our service offering is reliable collection of high-quality DNA samples to genotype for our database. ... Oragene-DNA is easy to use for our customers and consistently delivers superior samples for DNA analysis."

DNA Genotek's deal with WeGene follows its announcement this week that it has settled a patent-infringement and breach-of-contract dispute over its saliva DNA collection kits with

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.